{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:06:29Z","timestamp":1777428389580,"version":"3.51.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11837-4","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:36:02Z","timestamp":1777376162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rewired lipid metabolism in castration-resistant prostate cancer: molecular interplay between glucose metabolism and sterol synthesis"],"prefix":"10.1007","volume":"53","author":[{"given":"Harini Priyadharshini","family":"K B","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-5806","authenticated-orcid":false,"given":"Sumathy","family":"Arockiasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-9415","authenticated-orcid":false,"given":"Sriram","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"1","key":"11837_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"11837_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/iju.iju_27_24","volume":"40","author":"J Sankarapillai","year":"2024","unstructured":"Sankarapillai J, Krishnan S, Ramamoorthy T, Sudarshan KL, Mathur P (2024) Descriptive epidemiology of prostate cancer in India, 2012\u20132019: Insights from the National Cancer Registry Programme. Indian J Urol 40(3):167\u2013173. https:\/\/doi.org\/10.4103\/iju.iju_27_24","journal-title":"Indian J Urol"},{"key":"11837_CR3","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41388-021-01737-1","volume":"40","author":"J Zhou","year":"2021","unstructured":"Zhou J, Wang Y, Wu D et al (2021) Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. Oncogene 40:2625\u20132634. https:\/\/doi.org\/10.1038\/s41388-021-01737-1","journal-title":"Oncogene"},{"issue":"3","key":"11837_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.21037\/tau.2018.01.06","volume":"7","author":"Z Siddiqui","year":"2018","unstructured":"Siddiqui Z, Krauss D (2018) Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy. Transl Androl Urol 7(3):378\u2013389. https:\/\/doi.org\/10.21037\/tau.2018.01.06","journal-title":"Transl Androl Urol"},{"issue":"11","key":"11837_CR5","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.3390\/cancers12113339","volume":"12","author":"MA Lounis","year":"2020","unstructured":"Lounis MA, P\u00e9ant B, Leclerc-Desaulniers K et al (2020) Modulation of de novo lipogenesis improves response to enzalutamide treatment in prostate cancer. Cancers (Basel) 12(11):3339. https:\/\/doi.org\/10.3390\/cancers12113339","journal-title":"Cancers (Basel)"},{"issue":"11","key":"11837_CR6","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3390\/ijms20112626","volume":"20","author":"GE Stoykova","year":"2019","unstructured":"Stoykova GE, Schlaepfer IR (2019) Lipid metabolism and endocrine resistance in prostate cancer, and new opportunities for therapy. Int J Mol Sci 20(11):2626. https:\/\/doi.org\/10.3390\/ijms20112626","journal-title":"Int J Mol Sci"},{"issue":"5","key":"11837_CR7","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/ijms22052466","volume":"22","author":"K Mamouni","year":"2021","unstructured":"Mamouni K, Kallifatidis G, Lokeshwar BL (2021) Targeting mitochondrial metabolism in prostate cancer with triterpenoids. Int J Mol Sci 22(5):2466. https:\/\/doi.org\/10.3390\/ijms22052466","journal-title":"Int J Mol Sci"},{"key":"11837_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL (2021) Metabolic reprogramming in prostate cancer. Br J Cancer 125:1185\u20131196. https:\/\/doi.org\/10.1038\/s41416-021-01435-5","journal-title":"Br J Cancer"},{"issue":"1","key":"11837_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan MH, Li J, Xu HE, Melcher K, Yong EL (2015) Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 36(1):3\u201323. https:\/\/doi.org\/10.1038\/aps.2014.18","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"11837_CR10","first-page":"3","volume":"37","author":"RA Davey","year":"2016","unstructured":"Davey RA, Grossmann M (2016) Androgen receptor structure, function and biology: From bench to bedside. Clin Biochem Rev 37(1):3\u201315","journal-title":"Clin Biochem Rev"},{"issue":"11","key":"11837_CR11","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447\u20134454. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0249","journal-title":"Cancer Res"},{"issue":"18","key":"11837_CR12","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","volume":"17","author":"EA Mostaghel","year":"2011","unstructured":"Mostaghel EA, Marck BT, Plymate SR et al (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17(18):5913\u20135925. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0728","journal-title":"Clin Cancer Res"},{"key":"11837_CR13","doi-asserted-by":"publisher","first-page":"1021845","DOI":"10.3389\/fonc.2022.1021845","volume":"12","author":"M Labaf","year":"2022","unstructured":"Labaf M, Li M, Ting L et al (2022) Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2. Front Oncol 12:1021845. https:\/\/doi.org\/10.3389\/fonc.2022.1021845","journal-title":"Front Oncol"},{"issue":"6","key":"11837_CR14","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1210\/en.2017-00109","volume":"158","author":"Y Ho","year":"2017","unstructured":"Ho Y, Dehm SM (2017) Androgen receptor rearrangement and splicing variants in resistance to endocrine therapies in prostate cancer. Endocrinology 158(6):1533\u20131542. https:\/\/doi.org\/10.1210\/en.2017-00109","journal-title":"Endocrinology"},{"issue":"3","key":"11837_CR15","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP (2015) Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 4(3):365\u2013380","journal-title":"Transl Androl Urol"},{"key":"11837_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2020.05.007","volume":"485","author":"J Wang","year":"2020","unstructured":"Wang J, Xu W, Wang B et al (2020) GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett 485:45\u201355. https:\/\/doi.org\/10.1016\/j.canlet.2020.05.007","journal-title":"Cancer Lett"},{"issue":"4","key":"11837_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/ERC-17-0051","volume":"25","author":"MA White","year":"2018","unstructured":"White MA, Tsouko E, Lin C et al (2018) GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocr Relat Cancer 25(4):453\u2013469. https:\/\/doi.org\/10.1530\/ERC-17-0051","journal-title":"Endocr Relat Cancer"},{"key":"11837_CR18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","volume":"41","author":"L de Wet","year":"2022","unstructured":"de Wet L, Williams A, Gillard M et al (2022) SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene 41:1190\u20131202","journal-title":"Oncogene"},{"key":"11837_CR19","doi-asserted-by":"publisher","first-page":"113221","DOI":"10.1016\/j.celrep.2023.113221","volume":"42","author":"PD Crowell","year":"2023","unstructured":"Crowell PD, Giafaglione JM, Jones AE et al (2023) MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep 42:113221","journal-title":"Cell Rep"},{"key":"11837_CR20","doi-asserted-by":"publisher","unstructured":"Ibrahim SM, Ahmed Abdelmoaty AA, Abdelhaseb AH (2025) Evolving therapeutic paradigms in bladder cancer: the impact of immunotherapy and antibody-drug conjugates. Ann Urol Oncol 8(3):127\u2013137 https:\/\/doi.org\/10.32948\/auo.2025.11.09","DOI":"10.32948\/auo.2025.11.09"},{"key":"11837_CR21","doi-asserted-by":"crossref","unstructured":"Wang J, Xu W, Wang B, Lin G, Wei Y, Abudurexiti M, Zhu W, Liu C, Qin X, Dai B et al (2020) GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett 485:45\u201355","DOI":"10.1016\/j.canlet.2020.05.007"},{"issue":"22","key":"11837_CR22","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-23-0308","volume":"83","author":"Z Li","year":"2023","unstructured":"Li Z, Ning K, Zhao D et al (2023) Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling. Cancer Res 83(22):3753\u20133766. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0308","journal-title":"Cancer Res"},{"issue":"1","key":"11837_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41388-018-0414-x","volume":"38","author":"HJ Wang","year":"2019","unstructured":"Wang HJ, Pochampalli M, Wang LY et al (2019) KDM8\/JMJD5 as a dual coactivator of AR and PKM2 integrates AR\/EZH2 network and tumor metabolism in CRPC. Oncogene 38(1):17\u201332. https:\/\/doi.org\/10.1038\/s41388-018-0414-x","journal-title":"Oncogene"},{"issue":"Pt 2","key":"11837_CR24","doi-asserted-by":"publisher","first-page":"129635","DOI":"10.1016\/j.ijbiomac.2024.129635","volume":"260","author":"Y Yao","year":"2024","unstructured":"Yao Y, Chen X, Wang X et al (2024) Glycolysis related lncRNA SNHG3\/miR-139-5p\/PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance. Int J Biol Macromol 260(Pt 2):129635. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129635","journal-title":"Int J Biol Macromol"},{"key":"11837_CR25","doi-asserted-by":"publisher","unstructured":"Kim GJ, Jo HJ, Lee KJ, Choi JW, An JH (2018) Oleanolic acid induces p53-dependent apoptosis via the ERK\/JNK\/AKT pathway in prostate cancer xenografts. Oncotarget 9:26370\u201326386 https:\/\/doi.org\/10.18632\/oncotarget.25483","DOI":"10.18632\/oncotarget.25483"},{"key":"11837_CR26","doi-asserted-by":"crossref","unstructured":"Wang L, Stadlbauer B, Lyu C, Buchner A, Pohla H (2020) Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1. Am J Cancer Res 10:3784\u20133800","DOI":"10.21203\/rs.3.rs-58823\/v1"},{"issue":"7","key":"11837_CR27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1158\/1535-7163.MCT-23-0540","volume":"23","author":"T Uo","year":"2024","unstructured":"Uo T, Ojo KK, Sprenger CCT et al (2024) A compound that inhibits glycolysis in prostate cancer controls growth of advanced prostate cancer. Mol Cancer Ther 23(7):973\u2013994. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0540","journal-title":"Mol Cancer Ther"},{"key":"11837_CR28","doi-asserted-by":"crossref","unstructured":"Sharma D, Singh M, Rani R (2022) Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics. Semin Cancer Biol 87:184\u2013195","DOI":"10.1016\/j.semcancer.2022.11.007"},{"issue":"2","key":"11837_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/sj.pcan.4500712","volume":"7","author":"LC Costello","year":"2004","unstructured":"Costello LC, Feng P, Milon B et al (2004) Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 7(2):111\u2013117. https:\/\/doi.org\/10.1038\/sj.pcan.4500712","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"11837_CR30","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41556-023-01274-x","volume":"25","author":"JM Giafaglione","year":"2023","unstructured":"Giafaglione JM, Crowell PD, Delcourt AML et al (2023) Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment. Nat Cell Biol 25(12):1821\u20131832. https:\/\/doi.org\/10.1038\/s41556-023-01274-x","journal-title":"Nat Cell Biol"},{"issue":"14","key":"11837_CR31","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/pros.21368","volume":"71","author":"J Zou","year":"2011","unstructured":"Zou J, Milon BC, Desouki MM et al (2011) hZIP1 zinc transporter down-regulation in prostate cancer involves the overexpression of ras responsive element binding protein-1 (RREB-1). Prostate 71(14):1518\u20131524. https:\/\/doi.org\/10.1002\/pros.21368","journal-title":"Prostate"},{"issue":"3","key":"11837_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41391-018-0085-2","volume":"22","author":"S Zaidi","year":"2019","unstructured":"Zaidi S, Gandhi J, Joshi G et al (2019) The anticancer potential of metformin on prostate cancer. Prostate Cancer Prostatic Dis 22(3):351\u2013361. https:\/\/doi.org\/10.1038\/s41391-018-0085-2","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"11837_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.celrep.2018.03.032","volume":"23","author":"A Naguib","year":"2018","unstructured":"Naguib A, Mathew G, Reczek CR et al (2018) Mitochondrial complex I inhibitors expose a vulnerability for selective killing of PTEN-null cells. Cell Rep 23(1):58\u201367. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.032","journal-title":"Cell Rep"},{"issue":"1","key":"11837_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s42255-018-0002-y","volume":"1","author":"DA Bader","year":"2019","unstructured":"Bader DA, Hartig SM, Putluri V et al (2019) Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab 1(1):70\u201385. https:\/\/doi.org\/10.1038\/s42255-018-0002-y","journal-title":"Nat Metab"},{"issue":"1","key":"11837_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.path.2024.10.003","volume":"18","author":"GN Fanelli","year":"2025","unstructured":"Fanelli GN, Nuzzo PV, Pederzoli F et al (2025) Deciphering complexity: the molecular landscape of castration-resistant prostate cancer. Surg Pathol Clin 18(1):25\u201339. https:\/\/doi.org\/10.1016\/j.path.2024.10.003","journal-title":"Surg Pathol Clin"},{"issue":"19","key":"11837_CR36","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.3390\/cancers13194960","volume":"13","author":"M Mar\u00edn-Aguilera","year":"2021","unstructured":"Mar\u00edn-Aguilera M, Pereira MV, Jim\u00e9nez N et al (2021) Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes. Cancers (Basel) 13(19):4960. https:\/\/doi.org\/10.3390\/cancers13194960","journal-title":"Cancers (Basel)"},{"issue":"12","key":"11837_CR37","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.3390\/nu13124503","volume":"13","author":"A Matos","year":"2021","unstructured":"Matos A, Carvalho M, Bicho M et al (2021) Arginine and arginases modulate metabolism, tumor microenvironment and prostate cancer progression. Nutrients 13(12):4503. https:\/\/doi.org\/10.3390\/nu13124503","journal-title":"Nutrients"},{"issue":"4","key":"11837_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/cas.1317","volume":"108","author":"R Pichler","year":"2017","unstructured":"Pichler R, Fritz J, Heidegger I et al (2017) Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer. Cancer Sci 108(4):663\u2013670. https:\/\/doi.org\/10.1111\/cas.1317","journal-title":"Cancer Sci"},{"issue":"11","key":"11837_CR39","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s11255-019-02261-8","volume":"51","author":"I Selvi","year":"2019","unstructured":"Selvi I, Basar H, Baydilli N et al (2019) The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer. Int Urol Nephrol 51(11):1975\u20131983. https:\/\/doi.org\/10.1007\/s11255-019-02261-8","journal-title":"Int Urol Nephrol"},{"key":"11837_CR40","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1186\/s12885-019-6418-2","volume":"19","author":"E Zoni","year":"2019","unstructured":"Zoni E, Minoli M, Bovet C et al (2019) Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification. BMC Cancer 19:1216. https:\/\/doi.org\/10.1186\/s12885-019-6418-2","journal-title":"BMC Cancer"},{"issue":"10","key":"11837_CR41","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.3390\/cancers14102491","volume":"14","author":"M Thiruvalluvan","year":"2022","unstructured":"Thiruvalluvan M, Billet S, Bhowmick NA (2022) Antagonizing glutamine bioavailability promotes radiation sensitivity in prostate cancer. Cancers (Basel) 14(10):2491. https:\/\/doi.org\/10.3390\/cancers14102491","journal-title":"Cancers (Basel)"},{"issue":"4","key":"11837_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.plipres.2013.08.005","volume":"52","author":"N Zaidi","year":"2013","unstructured":"Zaidi N, Lupien L, Kuemmerle NB et al (2013) Lipogenesis and lipolysis: the pathways exploited by cancer cells to acquire fatty acids. Prog Lipid Res 52(4):585\u2013589. https:\/\/doi.org\/10.1016\/j.plipres.2013.08.005","journal-title":"Prog Lipid Res"},{"key":"11837_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.phrs.2018.02.022","volume":"131","author":"L Galbraith","year":"2018","unstructured":"Galbraith L, Leung HY, Ahmad I (2018) Lipid pathway deregulation in advanced prostate cancer. Pharmacol Res 131:177\u2013184. https:\/\/doi.org\/10.1016\/j.phrs.2018.02.022","journal-title":"Pharmacol Res"},{"key":"11837_CR44","doi-asserted-by":"publisher","first-page":"580617","DOI":"10.3389\/fonc.2020.580617","volume":"10","author":"T Uo","year":"2020","unstructured":"Uo T, Sprenger CCT, Plymate SR (2020) Androgen receptor signaling and metabolic and cellular plasticity during progression to castration resistant prostate cancer. Front Oncol 10:580617. https:\/\/doi.org\/10.3389\/fonc.2020.580617","journal-title":"Front Oncol"},{"issue":"3","key":"11837_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cmet.2014.01.019","volume":"19","author":"S Yue","year":"2014","unstructured":"Yue S, Li J, Lee SY et al (2014) Cholesteryl ester accumulation induced by PTEN loss and PI3K\/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 19(3):393\u2013406. https:\/\/doi.org\/10.1016\/j.cmet.2014.01.019","journal-title":"Cell Metab"},{"issue":"3","key":"11837_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jphs.2023.08.002","volume":"153","author":"J Tashiro","year":"2023","unstructured":"Tashiro J, Sugiura A, Warita T et al (2023) CYP11A1 silencing suppresses HMGCR expression via cholesterol accumulation and sensitizes CRPC cell line DU-145 to atorvastatin. J Pharmacol Sci 153(3):104\u2013112. https:\/\/doi.org\/10.1016\/j.jphs.2023.08.002","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"11837_CR47","doi-asserted-by":"publisher","first-page":"R175","DOI":"10.1530\/ERC-10-0339","volume":"18","author":"C Cai","year":"2011","unstructured":"Cai C, Balk SP (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 18(5):R175\u2013R182. https:\/\/doi.org\/10.1530\/ERC-10-0339","journal-title":"Endocr Relat Cancer"},{"key":"11837_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ebiom.2016.12.012","volume":"16","author":"TS Heuer","year":"2017","unstructured":"Heuer TS, Ventura R, Mordec K et al (2017) FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression. EBioMedicine 16:51\u201362. https:\/\/doi.org\/10.1016\/j.ebiom.2016.12.012","journal-title":"EBioMedicine"},{"issue":"2","key":"11837_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1073\/pnas.1808834116","volume":"116","author":"G Zadra","year":"2019","unstructured":"Zadra G, Ribeiro CF, Chetta P et al (2019) Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci USA 116(2):631\u2013640. https:\/\/doi.org\/10.1073\/pnas.1808834116","journal-title":"Proc Natl Acad Sci USA"},{"key":"11837_CR50","doi-asserted-by":"publisher","first-page":"13284","DOI":"10.1038\/s41598-019-49486-2","volume":"9","author":"HY Chuang","year":"2019","unstructured":"Chuang HY, Lee YP, Lin WC et al (2019) Fatty acid inhibition sensitizes androgen-dependent and -independent prostate cancer to radiotherapy via FASN\/NF-\u03baB pathway. Sci Rep 9:13284. https:\/\/doi.org\/10.1038\/s41598-019-49486-2","journal-title":"Sci Rep"},{"key":"11837_CR51","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau HT et al (2021) First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine 34:100797. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100797","journal-title":"EClinicalMedicine"},{"issue":"15","key":"11837_CR52","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1158\/0008-5472.CAN-05-0571","volume":"65","author":"K Brusselmans","year":"2005","unstructured":"Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV (2005) RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65(15):6719\u20136725. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0571","journal-title":"Cancer Res"},{"issue":"1","key":"11837_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/cbt.12.1.15721","volume":"12","author":"NV Guseva","year":"2011","unstructured":"Guseva NV, Rokhlin OW, Glover RA, Cohen MB (2011) TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Ther 12(1):80\u201385. https:\/\/doi.org\/10.4161\/cbt.12.1.15721","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"11837_CR54","doi-asserted-by":"publisher","first-page":"102720","DOI":"10.1016\/j.jbc.2022.102720","volume":"299","author":"S Liu","year":"2023","unstructured":"Liu S, Lai J, Feng Y et al (2023) Acetyl-CoA carboxylase 1 depletion suppresses de novo fatty acid synthesis and mitochondrial \u03b2-oxidation in castration-resistant prostate cancer cells. J Biol Chem 299(1):102720. https:\/\/doi.org\/10.1016\/j.jbc.2022.102720","journal-title":"J Biol Chem"},{"issue":"12","key":"11837_CR55","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/nm.3372","volume":"19","author":"MD Fullerton","year":"2013","unstructured":"Fullerton MD, Galic S, Marcinko K et al (2013) Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 19(12):1649\u20131654. https:\/\/doi.org\/10.1038\/nm.3372","journal-title":"Nat Med"},{"issue":"12","key":"11837_CR56","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ejheart.2008.10.004","volume":"10","author":"CJ Holubarsch","year":"2008","unstructured":"Holubarsch CJ, Colucci WS, Meinertz T et al (2008) The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 10(12):1255\u20131263. https:\/\/doi.org\/10.1016\/j.ejheart.2008.10.004","journal-title":"Eur J Heart Fail"},{"key":"11837_CR57","doi-asserted-by":"publisher","first-page":"56051","DOI":"10.18632\/oncotarget.17359","volume":"8","author":"TW Flaig","year":"2017","unstructured":"Flaig TW, Salzmann-Sullivan M, Su L et al (2017) Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget 8:56051\u201356065","journal-title":"Oncotarget"},{"issue":"10","key":"11837_CR58","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1541-7786.MCR-20-0570","volume":"18","author":"ZD Nassar","year":"2020","unstructured":"Nassar ZD, Mah CY, Centenera MM et al (2020) Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by HSP90 inhibition. Mol Cancer Res 18(10):1500\u20131511. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0570","journal-title":"Mol Cancer Res"},{"issue":"5","key":"11837_CR59","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.ajpath.2013.01.048","volume":"182","author":"T Migita","year":"2013","unstructured":"Migita T, Okabe S, Ikeda K et al (2013) Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact. Am J Pathol 182(5):1800\u20131810. https:\/\/doi.org\/10.1016\/j.ajpath.2013.01.048","journal-title":"Am J Pathol"},{"issue":"28","key":"11837_CR60","doi-asserted-by":"publisher","first-page":"44252","DOI":"10.18632\/oncotarget.10020","volume":"7","author":"M Xin","year":"2016","unstructured":"Xin M, Qiao Z, Li J et al (2016) miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer. Oncotarget 7(28):44252\u201344265. https:\/\/doi.org\/10.18632\/oncotarget.10020","journal-title":"Oncotarget"},{"issue":"28","key":"11837_CR61","doi-asserted-by":"publisher","first-page":"43713","DOI":"10.18632\/oncotarget.9666","volume":"7","author":"S Shah","year":"2016","unstructured":"Shah S, Carriveau WJ, Li J et al (2016) Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. Oncotarget 7(28):43713\u201343730. https:\/\/doi.org\/10.18632\/oncotarget.9666","journal-title":"Oncotarget"},{"issue":"7","key":"11837_CR62","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.chembiol.2011.05.009","volume":"18","author":"DK Nomura","year":"2011","unstructured":"Nomura DK, Lombardi DP, Chang JW et al (2011) Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 18(7):846\u2013856. https:\/\/doi.org\/10.1016\/j.chembiol.2011.05.009","journal-title":"Chem Biol"},{"key":"11837_CR63","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1756-0500-7-441","volume":"7","author":"M Cipriano","year":"2014","unstructured":"Cipriano M, Gouveia-Figueira S, Persson E et al (2014) The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. BMC Res Notes 7:441. https:\/\/doi.org\/10.1186\/1756-0500-7-441","journal-title":"BMC Res Notes"},{"issue":"6","key":"11837_CR64","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1158\/1535-7163.MCT-09-1064","volume":"9","author":"V Fritz","year":"2010","unstructured":"Fritz V, Benfodda Z, Rodier G et al (2010) Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 9(6):1740\u20131754. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-1064","journal-title":"Mol Cancer Ther"},{"key":"11837_CR65","doi-asserted-by":"publisher","first-page":"626971","DOI":"10.3389\/fonc.2021.626971","volume":"11","author":"B Guerra","year":"2021","unstructured":"Guerra B, Recio C, Aranda-Tav\u00edo H et al (2021) The mevalonate pathway, a metabolic target in cancer therapy. Front Oncol 11:626971. https:\/\/doi.org\/10.3389\/fonc.2021.626971","journal-title":"Front Oncol"},{"issue":"2","key":"11837_CR66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrurol.2016.199","volume":"14","author":"MA Alfaqih","year":"2017","unstructured":"Alfaqih MA, Allott EH, Hamilton RJ et al (2017) The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol 14(2):107\u2013119. https:\/\/doi.org\/10.1038\/nrurol.2016.199","journal-title":"Nat Rev Urol"},{"key":"11837_CR67","doi-asserted-by":"publisher","first-page":"149841","DOI":"10.1016\/j.bbrc.2024.149841","volume":"710","author":"A G\u00f6bel","year":"2024","unstructured":"G\u00f6bel A, P\u00e4hlig S, Motz A et al (2024) Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA reductase. Biochem Biophys Res Commun 710:149841. https:\/\/doi.org\/10.1016\/j.bbrc.2024.149841","journal-title":"Biochem Biophys Res Commun"},{"key":"11837_CR68","doi-asserted-by":"publisher","unstructured":"Kong Y, Cheng L, Mao F, Zhang Z, Zhang Y, Farah E, Bosler J, Bai Y, Ahmad N, Kuang S et al (2018) Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). J Biol Chem 293:14328\u201314341 https:\/\/doi.org\/10.1074\/jbc.RA118.004442","DOI":"10.1074\/jbc.RA118.004442"},{"key":"11837_CR69","doi-asserted-by":"publisher","unstructured":"Karkeet RM, Zekri AN, Sayed-Ahmed MM, Sherif GM, Salem SE, Abdelbary A, Fouad MA, Saad SY (2022) The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: randomized trial. PLoS One 17:e0278282 https:\/\/doi.org\/10.1371\/journal.pone.0278282","DOI":"10.1371\/journal.pone.0278282"},{"issue":"1","key":"11837_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/1541-7786.MCR-11-0206","volume":"10","author":"WC Huang","year":"2012","unstructured":"Huang WC, Li X, Liu J et al (2012) Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 10(1):133\u2013142. https:\/\/doi.org\/10.1158\/1541-7786.MCR-11-0206","journal-title":"Mol Cancer Res"},{"issue":"4","key":"11837_CR71","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1535-7163.MCT-13-0797","volume":"13","author":"X Li","year":"2014","unstructured":"Li X, Chen YT, Hu P, Huang WC (2014) Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther 13(4):855\u2013866. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0797","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"11837_CR72","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.bbagrm.2014.07.013","volume":"1839","author":"V Infantino","year":"2014","unstructured":"Infantino V, Iacobazzi V, Menga A et al (2014) A key role of the mitochondrial citrate carrier (SLC25A1) in TNF\u03b1- and IFN\u03b3-triggered inflammation. Biochim Biophys Acta Gene Regul Mech 1839(11):1217\u20131225. https:\/\/doi.org\/10.1016\/j.bbagrm.2014.07.013","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"11837_CR73","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fonc.2018.00170","volume":"8","author":"J Hlouschek","year":"2018","unstructured":"Hlouschek J, Hansel C, Jendrossek V, Matschke J (2018) The mitochondrial citrate carrier (SLC25A1) sustains redox homeostasis and mitochondrial metabolism supporting radioresistance of cancer cells with tolerance to cycling severe hypoxia. Front Oncol 8:170. https:\/\/doi.org\/10.3389\/fonc.2018.00170","journal-title":"Front Oncol"},{"key":"11837_CR74","doi-asserted-by":"publisher","unstructured":"Icard P, Poulain L, Lincet H (2012) Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta 1825:111\u2013116 https:\/\/doi.org\/10.1016\/j.bbcan.2011.10.007","DOI":"10.1016\/j.bbcan.2011.10.007"},{"issue":"1","key":"11837_CR75","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12672-023-00830-z","volume":"14","author":"X You","year":"2023","unstructured":"You X, Huang L, Huang O et al (2023) A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer. Discov Oncol 14(1):207. https:\/\/doi.org\/10.1007\/s12672-023-00830-z","journal-title":"Discov Oncol"},{"key":"11837_CR76","doi-asserted-by":"publisher","unstructured":"Catalina-Rodriguez O, Kolukula VK, Tomita Y, Preet A, Palmieri F, Wellstein A, Byers S, Giaccia AJ, Avantaggiati ML (2012) The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget 3:1220\u20131235 https:\/\/doi.org\/10.18632\/oncotarget.714","DOI":"10.18632\/oncotarget.714"},{"key":"11837_CR77","doi-asserted-by":"publisher","unstructured":"Holubarsch CJ, Colucci WS, Meinertz T et al (2008) The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 10(12):1255\u20131263 https:\/\/doi.org\/10.1016\/j.ejheart.2008.10.004","DOI":"10.1016\/j.ejheart.2008.10.004"},{"issue":"12","key":"11837_CR78","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701\u2013711. https:\/\/doi.org\/10.1038\/nrc4016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"11837_CR79","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bcp.14972","volume":"88","author":"LM Scailteux","year":"2022","unstructured":"Scailteux LM, Despas F, Balusson F et al (2022) Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients. Br J Clin Pharmacol 88(1):336\u2013346. https:\/\/doi.org\/10.1111\/bcp.14972","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"11837_CR80","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3390\/cancers16162777","volume":"16","author":"M Rahman","year":"2024","unstructured":"Rahman M, Akter K, Ahmed KR et al (2024) Synergistic strategies for castration-resistant prostate cancer: targeting AR-V7, exploring natural compounds, and optimizing FDA-approved therapies. Cancers (Basel) 16(16):2777. https:\/\/doi.org\/10.3390\/cancers16162777","journal-title":"Cancers (Basel)"},{"key":"11837_CR81","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41598-020-57932-9","volume":"10","author":"PKB Nagesh","year":"2020","unstructured":"Nagesh PKB, Chowdhury P, Hatami E et al (2020) Tannic acid inhibits lipid metabolism and induces ROS in prostate cancer cells. Sci Rep 10:980. https:\/\/doi.org\/10.1038\/s41598-020-57932-9","journal-title":"Sci Rep"},{"issue":"3","key":"11837_CR82","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jtcme.2020.02.002","volume":"10","author":"SH Kim","year":"2020","unstructured":"Kim SH, Singh KB, Hahm ER et al (2020) Withania somnifera root extract inhibits fatty acid synthesis in prostate cancer cells. J Tradit Complement Med 10(3):188\u2013197. https:\/\/doi.org\/10.1016\/j.jtcme.2020.02.002","journal-title":"J Tradit Complement Med"},{"key":"11837_CR83","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.molmet.2019.04.003","volume":"25","author":"J Longo","year":"2019","unstructured":"Longo J, Mullen PJ, Yu R et al (2019) An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Mol Metab 25:119\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.04.003","journal-title":"Mol Metab"},{"issue":"10","key":"11837_CR84","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1158\/1535-7163.MCT-19-0046","volume":"18","author":"KB Singh","year":"2019","unstructured":"Singh KB, Hahm ER, Pore SK, Singh SV (2019) Leelamine is a novel lipogenesis inhibitor in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 18(10):1800\u20131810. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0046","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"11837_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2014.03.015","volume":"349","author":"Y Gao","year":"2014","unstructured":"Gao Y, Islam MS, Tian J et al (2014) Inactivation of ATP citrate lyase by cucurbitacin B, a bioactive compound from cucumber, inhibits prostate cancer growth. Cancer Lett 349(1):15\u201325. https:\/\/doi.org\/10.1016\/j.canlet.2014.03.015","journal-title":"Cancer Lett"},{"issue":"25","key":"11837_CR86","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.1021\/jf301499e","volume":"60","author":"VC Lin","year":"2012","unstructured":"Lin VC, Tsai YC, Lin JN et al (2012) Activation of AMPK by pterostilbene suppresses lipogenesis and cell-cycle progression in p53 positive and negative human prostate cancer cells. J Agric Food Chem 60(25):6399\u20136407. https:\/\/doi.org\/10.1021\/jf301499e","journal-title":"J Agric Food Chem"},{"issue":"5","key":"11837_CR87","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bcp.2010.12.014","volume":"81","author":"DB Jump","year":"2011","unstructured":"Jump DB, Torres-Gonzalez M, Olson LK (2011) Soraphen A, an inhibitor of acetyl-CoA carboxylase activity, interferes with fatty acid elongation. Biochem Pharmacol 81(5):649\u2013660. https:\/\/doi.org\/10.1016\/j.bcp.2010.12.014","journal-title":"Biochem Pharmacol"},{"key":"11837_CR88","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.addr.2020.07.013","volume":"159","author":"LM Butler","year":"2020","unstructured":"Butler LM, Perone Y, Dehairs J et al (2020) Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev 159:245\u2013293. https:\/\/doi.org\/10.1016\/j.addr.2020.07.013","journal-title":"Adv Drug Deliv Rev"},{"key":"11837_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-026-01100-z","author":"S Bleve","year":"2026","unstructured":"Bleve S, Ravera F, Rodrigues S et al (2026) Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor\u2013targeting therapy. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-026-01100-z","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"11837_CR90","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/biom12091306","volume":"12","author":"Q Hao","year":"2022","unstructured":"Hao Q, Wu Y, Vadgama JV, Wang P (2022) Phytochemicals in inhibition of prostate cancer: evidence from molecular mechanisms studies. Biomolecules 12(9):1306. https:\/\/doi.org\/10.3390\/biom12091306","journal-title":"Biomolecules"},{"key":"11837_CR91","doi-asserted-by":"publisher","unstructured":"Kiskov\u00e1 T, Kassayov\u00e1 M (2019) Resveratrol action on lipid metabolism in cancer. Int J Mol Sci 20:2704 https:\/\/doi.org\/10.3390\/ijms20112704","DOI":"10.3390\/ijms20112704"},{"key":"11837_CR92","doi-asserted-by":"publisher","unstructured":"Jonnalagadda B, Arockiasamy S: Synergistic anticancer effect of CDRI-08 and abiraterone acetate against castration resistant prostate cancer targeting PI3K\/Akt pathway. Iranian Journal of Basic Medical Sciences 2025, 28(9): 1163\u20131170 https:\/\/doi.org\/10.22038\/ijbms.2025.85330.18441","DOI":"10.22038\/ijbms.2025.85330.18441"},{"issue":"10","key":"11837_CR93","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.bbalip.2013.03.010","volume":"1831","author":"G Zadra","year":"2013","unstructured":"Zadra G, Photopoulos C, Loda M (2013) The fat side of prostate cancer. Biochim Biophys Acta 1831(10):1518\u20131532. https:\/\/doi.org\/10.1016\/j.bbalip.2013.03.010","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"11837_CR94","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1021\/pr401106h","volume":"13","author":"AK Kaushik","year":"2014","unstructured":"Kaushik AK, Vareed SK, Basu S et al (2014) Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res 13(2):1088\u20131100. https:\/\/doi.org\/10.1021\/pr401106h","journal-title":"J Proteome Res"},{"key":"11837_CR95","doi-asserted-by":"publisher","unstructured":"Dai J, Lu Y, Roca H, Keller JM, McCauley LK, Keller ET (2017) Immune mediators in the tumor microenvironment of prostate cancer. Chin J Cancer 36:29 https:\/\/doi.org\/10.1186\/s40880-017-0198-3","DOI":"10.1186\/s40880-017-0198-3"},{"key":"11837_CR96","doi-asserted-by":"publisher","unstructured":"Culig Z, Puhr M (2018) Interleukin-6 and prostate cancer: current developments and unsolved questions. Mol Cell Endocrinol 462:25\u201330 https:\/\/doi.org\/10.1016\/j.mce.2017.03.012","DOI":"10.1016\/j.mce.2017.03.012"},{"key":"11837_CR97","doi-asserted-by":"publisher","unstructured":"Bonollo F, Thalmann GN, Kruithof-de Julio M, Karkampouna S. The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. Cancers (Basel). 2020 Jul 13;12(7):1887. https:\/\/doi.org\/10.3390\/cancers12071887","DOI":"10.3390\/cancers12071887"},{"key":"11837_CR98","doi-asserted-by":"publisher","unstructured":"P\u00e9rtega-Gomes N, Vizca\u00edno JR, Attig J, Jurmeister S, Lopes C, Baltazar F (2014) A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer 14:352 https:\/\/doi.org\/10.1186\/1471-2407-14-352","DOI":"10.1186\/1471-2407-14-352"},{"key":"11837_CR99","doi-asserted-by":"publisher","unstructured":"Krahmer N, Farese RV Jr, Walther TC (2013) Balancing the fat: lipid droplets and human disease. EMBO Mol Med 5:973\u2013983 https:\/\/doi.org\/10.1002\/emmm.201100671","DOI":"10.1002\/emmm.201100671"},{"key":"11837_CR100","doi-asserted-by":"publisher","unstructured":"Conte M, Franceschi C, Sandri M, Salvioli S: Increased Plin2 expression in human skeletal muscle is associated with sarcopenia and muscle weakness. PLoS One 2013, 8(8): e73709 https:\/\/doi.org\/10.1371\/journal.pone.0073709","DOI":"10.1371\/journal.pone.0073709"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11837-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:36:07Z","timestamp":1777376167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11837-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11837"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11837-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"689"}}